Instrument Inactif

Autres langues ValiRx Plc London S.E.

Actions

GB00B23N9136

Recherche biotechnologique et médicale

Cours en clôture London S.E.
- ^GBX	-

10/08	Cytolytix, filiale de ValiRx, sur le point d'obtenir un brevet européen " significatif »	AN
10/08	Une filiale de ValiRx reçoit une intention de délivrance de brevet européen pour un peptide anticancéreux	MT

Autres langues

10/08	ValiRx subsidiary Cytolytix nears "significant" European patent win
10/08	ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide
10/08	Cytolytix Limited Receives Notification of Intention to Grant European Patent for Polyleucine-Based Peptides as Anti-Cancer Agents
18/07	Valirx plc Announces Termination of Catherine Jane Tralau-Stewart from Director Role, Effective July 17, 2026
23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows
22/06	Maintel fundraising completes; ValiRx ends deal
22/06	Valirx plc Announces the Resignation of Tralau-Stewart as Chair of the Advisory Board and Non-Executive Director
22/06	ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2025
22/06	Earnings Flash (VAL.L) ValiRx Plc Reports FY25 Revenue GBP31,372
02/06	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio
27/05	ValiRx subsidiary Cytolytix granted "core" European patent
27/05	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent
21/05	ValiRx Raises Funds via Retail Offering
18/05	ValiRx to Raise Funds via Retail Offer
15/05	IAG launches new buyback; Forgent settles legal case
15/05	WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach
15/05	ValiRx Seeks to Raise Over GBP1 Million via Share Issue
14/05	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down
31/03	ValiRx PLC Announces Change Of Registered Office
03/03	ValiRx establishes veterinary oncology-focused subsidiary
02/03	ValiRx Forms Veterinary Oncology Unit
02/03	ValiRx plc Sets Up Wholly Owned Subsidiary ValiRx Animal Health Limited
09/01	Life Science REIT portfolio valuation declines 7.8%
09/01	ValiRx Signs Cancer Drug Evaluation Deal With McGill, IRICoR in Canada
04/11	Unilever targets early December Ice Cream spin-off